Home›Clindamycin In 5 Percent Dextrose

Clindamycin In 5 Percent Dextrose

Also known as: Clindamycin In 5 Percent Dextrose

Lincosamide Antibacterial

Route: Intravenous

Check Clindamycin In 5 Percent Dextrose Interactions →

3 interactions on record⛔ Black Box Warning

Clindamycin In 5 Percent Dextrose has 3 known drug interactions based on U.S. FDA drug labeling data. Notable interactions include combinations with Adrenergic Blockers, Rifampin. Patients taking Clindamycin In 5 Percent Dextrose should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 3
Moderate: 2
Minor: 1

Moderate (2)

Clindamycin In 5 Percent Dextrose + Adrenergic Blockers— Clindamycin has neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents; us…
Clindamycin In 5 Percent Dextrose + Rifampin— Strong CYP3A4 inducer may reduce plasma concentrations of clindamycin; monitor for loss of effectiveness.

Minor (1)

Clindamycin In 5 Percent Dextrose + Clindamycin— Drug Interactions Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of ot…

Clindamycin In 5 Percent Dextrose + Adrenergic Blockers🟡Moderate

Clindamycin has neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents; use with caution in patients receiving such agents.

Clindamycin In 5 Percent Dextrose + Rifampin🟡Moderate

Strong CYP3A4 inducer may reduce plasma concentrations of clindamycin; monitor for loss of effectiveness.

Clindamycin In 5 Percent Dextrose + Clindamycin🟢Minor

Drug Interactions Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Clindamycin is metabolized predominantly by CYP3A4, and to a lesser extent by CYP3A5, to the major metabolite clindamycin sulfoxide and minor metabolite N-desmethylclindamycin. Therefore, inhibitors of CYP3A4 and CYP3A5 may increase plasma concentrations of clindamycin and inducers of these isoenzymes may reduce plasma concentrations of clindamycin.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.